Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washington Convention Center in Washington, DC. The presentation, which was accepted as “late-breaking research: clinical trials,” will provide details of XBiotech's recent Phase 2 clinical trial results in 42 HS patients who received 400mg subcutaneous weekly doses of bermekimab in a 12-week treatment regimen.

The study involved two treatment groups of subjects: those who had failed prior anti-TNF therapy (n=24); and those with no prior anti-TNF treatment history (n=18). The study was conducted at eleven different dermatology research centers across the US.

Dr.  Gottlieb, a Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, NY, commented, “I am looking forward to presenting these very exciting results for a new drug that can help address a significant unmet need for patients suffering from hidradenitis suppurativa.”

A major finding in the study was a significant treatment-related reduction of pain in the HS patients. Pain is widely recognized among experts as a key objective for HS treatment, but this symptom has been largely unaddressed by available approved therapies. No approved monotherapy for HS has shown a significant effect on pain.

XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy, and tolerability.

—Stefanie Tuleya